AstraZeneca in Lithuania
E-mail: astrazeneca.lithuania@astrazeneca.com
Web: https://www.astrazeneca.com/
Address:
-
UAB „AstraZeneca Lietuva“
Spaudos g. 6-1, LT-05132, Vilnius, Lietuva
Phone: +370 5 266 0550
Other AstraZeneca's locations around the world
Europe
North America
Asia
Africa
Oceania
Clinical Trials sponsored by AstraZeneca
-
AstraZenecaAstraZeneca K.K.CompletedNonalcoholic SteatohepatitisUnited States, Italy, Thailand, Germany, Brazil, China, Malaysia, Taiwan, Chile, Spain, Japan, Hong Kong, Argentina, India, Mexico, Vietnam, Singapore, Philippines, Peru, Colombia, South Korea, Turkey (Türkiye)
-
AstraZenecaAstraZeneca K.K.CompletedDyslipidemiaUnited States, Canada, Spain, Hungary, Czechia, Denmark, Slovakia, Japan
-
AstraZenecaNot yet recruitingGastric Cancer | Gastroesophageal Junction Cancer
-
AstraZenecaNot yet recruitingChronic Rhinosinusitis With Nasal Polyps
-
AstraZenecaRecruitingObesity or OverweightArgentina, Italy, Germany, United States, France, Australia, China, Poland, Taiwan, Bulgaria, Canada, India, Brazil, Czechia, Japan, South Korea
-
AstraZenecaNot yet recruitingDiabetes Mellitus, Type 2 | Obesity or OverweightUnited States, Germany, Spain, Hungary, Taiwan, Chile, Argentina, Australia, Canada, Poland, China, Slovakia, United Kingdom, Japan, India, South Korea
-
AstraZenecaNot yet recruitingHepatic ImpairmentUnited States
-
AstraZenecaRecruitingObesity or Overweight | Weight-Related Comorbidity | With/Without Diabetes Mellitus, Type 2Argentina, Denmark, United States, Japan, China, Israel, Canada, Sweden, Brazil, United Kingdom, Turkey (Türkiye)
-
AstraZenecaNot yet recruitingCarcinoma, Non-Small-Cell Lung
-
AstraZenecaNot yet recruitingLupus Erythematosus, SystemicChina
About AstraZeneca
We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. Our purpose and values help explain why we exist, what we hope to accomplish, the behaviours we value, how we will achieve our goals, and the promise of our brand to our stakeholders.